Since KCa3.1 is significantly expressed and functional in SFs of RA patients, the study focused on the blocking of this channel with TRAM-34, a pore-blocking KCa3.1 inhibitor (Friebel et al., 2015). The gene discussed is KCNN4; the disease is rheumatoid arthritis.